Anifrolumab (Saphnelo) March 6, 2024

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

Anifrolumab Now Covered Under BC PharmaCare for Lupus Treatment

Read

Belimumab for Lupus Nephritis in BC Now Approved Under BC Renal Formulary

Read

A Mother’s Lupus Story: Carolina and Luca’s Journey

Read